February 24, 2017 Biomarker Qualification: Collaboration, Strategy, and Implementation Biomarker Qualification: Collaboration, Strategy, and Implementation Webinar February 24th, 2017 Presenter: John Michael Sauer, Ph
February 20, 2017 C-Path CEO Dr. Martha Brumfield Interviewed for RAPS Regulatory Exchange Member Spotlight
February 1, 2017 Validity of Low-Contrast Letter Acuity as a Visual Performance Outcome Measure for Multiple Sclerosis
February 1, 2017 The Nine-Hole Peg Test as a Manual Dexterity Performance Measure for Multiple Sclerosis
February 1, 2017 Validity of the Timed 25-Foot Walk as an Ambulatory Performance Outcome Measure for Multiple Sclerosis
February 1, 2017 A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease
February 1, 2017 Validity of the Symbol Digit Modalities Test as a Cognition Performance Outcome Measure for Multiple Sclerosis
January 31, 2017 Accelerating drug development for Alzheimer’s disease through the use of data standards
January 31, 2017 Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team
January 31, 2017 Clinically Meaningful Outcomes in Early Alzheimer Disease: A Consortia-Driven Approach to Identifying What Matters to Patients
